Werewolf Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Werewolf Therapeutics R&D Spending Growth & History (HOWL)
Werewolf Therapeutics's r&d spending was $44.8M for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44.8M | −$11.6M | −20.56% |
| 2024 | 2024-12-31 | $56.4M | $14.7M | +35.09% |
| 2023 | 2023-12-31 | $41.8M | −$12.0M | −22.29% |
| 2022 | 2022-12-31 | $53.8M | $18.5M | +52.43% |
| 2021 | 2021-12-31 | $35.3M | $18.6M | +111.94% |
| 2020 | 2020-12-31 | $16.6M | — | — |
Werewolf Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.2M | −$7.0M | −53.12% |
| Q1 2026 | 2026-03-31 | $8.2M | −$4.9M | −37.64% |
| Q4 2025 | 2025-12-31 | $6.9M | −$8.8M | −55.92% |
| Q3 2025 | 2025-09-30 | $11.6M | −$894,000 | −7.14% |
| Q2 2025 | 2025-06-30 | $13.1M | −$2.1M | −13.93% |
| Q1 2025 | 2025-03-31 | $13.1M | $212,000 | +1.64% |
| Q4 2024 | 2024-12-31 | $15.7M | $6.1M | +62.99% |
| Q3 2024 | 2024-09-30 | $12.5M | $1.7M | +15.59% |
| Q2 2024 | 2024-06-30 | $15.3M | $5.7M | +59.36% |
| Q1 2024 | 2024-03-31 | $12.9M | $1.2M | +10.27% |
| Q4 2023 | 2023-12-31 | $9.6M | −$6.2M | −39.16% |
| Q3 2023 | 2023-09-30 | $10.8M | −$2.2M | −17.08% |
| Q2 2023 | 2023-06-30 | $9.6M | −$4.3M | −30.99% |
| Q1 2023 | 2023-03-31 | $11.7M | $761,000 | +6.95% |
| Q4 2022 | 2022-12-31 | $15.9M | $2.5M | +18.35% |
| Q3 2022 | 2022-09-30 | $13.1M | $3.3M | +33.54% |
| Q2 2022 | 2022-06-30 | $13.9M | $6.6M | +91.15% |
| Q1 2022 | 2022-03-31 | $10.9M | $6.1M | +127.22% |
| Q4 2021 | 2021-12-31 | $13.4M | $8.1M | +153.50% |
| Q3 2021 | 2021-09-30 | $9.8M | $5.0M | +103.39% |
| Q2 2021 | 2021-06-30 | $7.3M | $3.5M | +92.20% |
| Q1 2021 | 2021-03-31 | $4.8M | $2.1M | +74.34% |
| Q4 2020 | 2020-12-31 | $5.3M | — | — |
| Q3 2020 | 2020-09-30 | $4.8M | — | — |
| Q2 2020 | 2020-06-30 | $3.8M | — | — |
| Q1 2020 | 2020-03-31 | $2.8M | — | — |
Werewolf Therapeutics r&d spending trends
Over the last five fiscal years, Werewolf Therapeutics's r&d spending increased from $16.6M to $44.8M, a change of $28.2M. The latest reported quarter, Q2 2026, shows $6.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗